Clinical Application of Potassium Magnesium Aspartate, October 11, 1999

Clinical Application of Potassium Magnesium Aspartate, October 11, 1999

This medication is also known as Panandine, available in both injectable and tablet forms. For injections: a 10 mL ampoule contains 0.4 g of magnesium aspartate and 0.452 g of potassium aspartate. Typically, 20–50 mL is diluted in 250–500 mL of 5% glucose solution for intravenous infusion once daily, with a course lasting 10–15 days. Patients with acute myocardial infarction may receive 10 mL diluted in 5% glucose solution, administered as a 20 mL intravenous push twice daily. For tablets: each contains 0.14 g of magnesium aspartate and 0.158 g of potassium aspartate, two tablets three times daily by mouth. The primary indication for this drug is arrhythmia, effective against various types of arrhythmia, especially those caused by myocarditis, digitalis toxicity, pre-excitation, and hypokalemia, with a 100% efficacy rate. Additionally, it is also effective against arrhythmias caused by coronary heart disease, hypertensive heart disease, and other cardiac conditions, with an efficacy rate exceeding 85%. Among arrhythmias, atrial fibrillation, premature ventricular contractions, and paroxysmal tachycardia are particularly effective. This drug can also treat refractory heart failure.